2. Classification and Diagnosis of Diabetes:Standards of Care in Diabetes—2023

Abstract

The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.

GLP-1R Signaling and Functional Molecules in Incretin Therapy

“…Unfortunately, in recent decades, the population of adolescents and young adults with T2DM is increasing [ 159 ], which highlights the urgency of early diagnosis. Although conventional diabetes diagnostic indicators such as fasting plasma glucose and HbA1c are simple and practicable, they do not provide the specificity to distinguish pathways related to pancreatic β-cell mass destruction or dysfunction [ 160 , 161 ]. Noninvasive imaging tools (such as PET and MRI) and novel biomarkers can provide abundant pathological characteristics about β-cells [ 162 , 163 , 164 , 165 , 166 ] or related diagnostic information [ 140 , 167 , 168 , 169 , 170 , 171 , 172 , 173 ], which may help improve monitoring disease progress and severity, support the development of diabetes management strategies, evaluate and even guide drug development [ 174 , 175 ].…”

Editorial: Non-coding RNA in diabetes and cardiovascular diseases

“…Non-coding RNA in diabetes and cardiovascular diseases Diabetes mellitus (DM) is a wide cluster of metabolic dysfunctions characterized by hyperglycemia resulting from insulin resistance, inadequate insulin secretion, or excessive glucagon secretion (1). The global diabetes prevalence in 2021 is estimated to be 10.5% (536.6 million people) (Li et al).…”

The Role of Advanced Glycation End Products on Dyslipidemia

“…Type 2 DM is a condition characterized by a hyperglycemia due to a relative insulin deficiency and peripheral insulin resistance [ 4 ]. Chronic hyperglycemia triggers multiple pathophysiological processes and affects the structure and function of virtually all biomolecules.…”